Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 1618

Method to produce induced Pluripotent Stem (iPS) Cells from non-embryonic human

Inventors: George Daley, In-Hyun Park, Suneet Agarwal, Paul Lerou

Invention Types: Therapeutics

Research Areas: Personalized Medicine, Regenerative Medicine, Stem Cell

Keywords: Disease Model, Stem/Progenitor Cell, Tissue Engineering, Gene Therapy

For More Information Contact:  Meyer, Abbie

 

Invention Description:

Using ectopic expression of transcription factors including Oct4, Sox2, Klf4 and Myc and other factors in human fibroblasts and mesenchymal cells, the Daley group has created induced pluripotent stem (iPS) cells from fetal, neonatal and adult primary cells. These iPS cells, which can be made using a single polycistronic vector, resemble embryonic stem cells in morphology and gene expression and in their pluripotent capacity.

In addition to healthy iPS cells, Daley has made iPS from individuals with genetic diseases including ADA-SCID, Gaucher's Disease, Huntington's Disease, Type 1 Diabetes Mellitus, Duchenne and Becker's Muscular Dystrophy, Down Syndrome and others.

Applications:

Platform technology: Generation of patient- and disease-specific models for drug discover and Cell lines many lines are available for internal research use.

Competitive Advantages:

Pluripotent cells that avoid use of ESCs, Creation of iPS from individuals with genetic mutations, Study of known genotype on phenotype, Model of human diseases, access to cells along the development pathway.

Business Opportunity:

License of IP and normal and disease-specific iPS lines for drug screening.

Key Publications: Reprogramming of human somatic cells to pluripotency with defined factors
In-Hyun Park1, Rui Zhao1, Jason A. West, Akiko Yabuuchi, Hongguang Huo, Tan A. Ince, Paul H. Lerou,
M. William Lensch & George Q. Daley
doi:10.1038/nature06534

Related Publications: Cell. 2008 Sep 5;134(5):877-86.
Nat Protoc. 2008;3(7):1180-6.
Nature. 2008 Jan 10;451(7175):141-6.

IPStatus: Pat. Pend.